Interesting article I found online on Midkine and COVID 19. Has anyone seen this, it's been reviewed by Senior USA Gov Health officials yet seems no mention from Cellmid or Lyramid?
All shareholders should read this article IMHO.
Summary quotation follows:
"Taken in all, we hypothesize a key role of Midkine, particularly in organ dysfunction at the basis of COVID-19 pathogenesis and also propose such protein as a potential biomarker (Table 1) of pathophysiological conditions and as a key target for new potential COVID-19 therapeutical strategies by employing anti-Midkine monoclonal antibodies to be specifically prepared for clinical use in humans."
Source
https://www.frontiersin.org/articles/10.3389/fphys.2020.616552/full
Reference
AUTHOR=Sanino Giulia, Bosco Martino, Terrazzano Giuseppe TITLE=Physiology of Midkine and Its Potential Pathophysiological Role in COVID-19 JOURNAL=Frontiers in Physiology VOLUME=11 YEAR=2020 PAGES=1682 URL=https://www.frontiersin.org/article/10.3389/fphys.2020.616552 DOI=10.3389/fphys.2020.616552 ISSN=1664-042X ABSTRACT=SARS-CoV2 infection not only causes abnormal severe pneumonia but also induces other relevant pathophysiological effects on several tissues and organs. In this regard, the clinical complications observed in COVID-19 include acute coronary syndrome, pulmonary thromboembolism, myocarditis and, in the severe cases, the occurrence of disseminated intravascular coagulation. Literature on COVID-19 highlighted the central role of the Renin Angiotensin Aldosterone System in the determinism of SARS-CoV2 cellular internalization in the target tissues. Lung degeneration and respiratory distress appear to be dependent on the perturbance of physiological mechanisms, such as the uncontrolled release of pro-inflammatory cytokines, a dysregulation of the fibrinolytic coagulative cascade and the hyperactivation of immune effector cells. In this mini review, we address the physiology of Midkine, a growth factor able to bind heparin, and its pathophysiological potential role in COVID-19 determinism. Midkine increases in many inflammatory and autoimmune conditions and correlates with several dysfunctional immune-inflammatory responses that appear to show similarities with the pathophysiological elicited by SARS-CoV2. Midkine, together with its receptor, could facilitate the virus entry, fostering its accumulation and increasing its affinity with Ace2 receptor. We also focus on Netosis, a particular mechanism of pathogen clearance exerted by neutrophils, which under certain pathological condition becomes dysfunctional and can cause tissue damage. Moreover, we highlight the mechanism of autophagy that the new coronavirus could try to escape in order to replicate itself, as well as on pulmonary fibrosis induced by hypoxia and on the release of cytokines and mediators of inflammation, correlating the interplay between Midkine and SARS-CoV2.
- Forums
- ASX - By Stock
- AN1
- Midkine and COVID 19
Midkine and COVID 19
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1197315 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 59888 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1197315 | 0.007 |
4 | 665639 | 0.006 |
1 | 300000 | 0.005 |
3 | 825000 | 0.004 |
1 | 600000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 59888 | 2 |
0.009 | 280000 | 1 |
0.010 | 157763 | 1 |
0.012 | 4000 | 1 |
0.013 | 750000 | 1 |
Last trade - 16.12pm 19/08/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
Day chart unavailable